Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.
about
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.NaCurrent concepts in the pathophysiology and treatment of aplastic anemiaImmune Mechanisms in Myelodysplastic SyndromeImmunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumabClinical Prognostic Factors in 86 Chinese Patients with Primary Myelodysplastic Syndromes and Trisomy 8: A Single Institution Experience.The relationship between idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and autoimmunity.Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome.T-cell receptor Vβ skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS.Current therapy of myelodysplastic syndromesT-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapyMyelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes.Protein kinase R as mediator of the effects of interferon (IFN) gamma and tumor necrosis factor (TNF) alpha on normal and dysplastic hematopoiesisImmune dysregulation in myelodysplastic syndrome.Biology of BM failure syndromes: role of microenvironment and niches.Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndromeTrisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins.Molecular pathophysiology of myelodysplastic syndromes.Can molecular profiling of cytogenetic subgroups draw a roadmap for individualizing therapy in myelodysplastic syndromes?The revolution of myelodysplastic syndromes.Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes.The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes.Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance.Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to successDiagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.Immunological derangement in hypocellular myelodysplastic syndromes.Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes?Update on the pharmacotherapy for myelodysplastic syndromes.Higher Risk Myelodysplastic Syndromes in Patients with Well-Controlled HIV Infection: Clinical Features, Treatment, and Outcome.The inflammatory microenvironment in MDS.Emerging biological therapies for the treatment of myelodysplastic syndromes.Pediatric intestinal Behçet disease complicated by myeloid malignancies.Recent advances in understanding clonal haematopoiesis in aplastic anaemia.Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias.Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndromeChronic relapsing remitting Sweet syndrome--a harbinger of myelodysplastic syndrome.Techniques for detecting chromosomal aberrations in myelodysplastic syndromesCytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview.
P2860
Q24599447-D7FD0FD3-481E-40E4-9C9C-7AD6ADCD18D0Q24685812-F2C0E651-BB60-421A-8865-0CD2E048B96CQ26744500-3E186B65-782A-4CD3-87F1-A65A7A590869Q26864200-F7952040-BFD7-4683-8FD5-6ECBED97B319Q33429792-A4264549-BEEB-4ACD-A88D-C347655226C8Q33442467-AA83AA98-0A61-43D6-AB1B-6859CECA8096Q33679140-4955D4DE-49A9-4706-A26B-59A53284CBDEQ33702157-8F5E55F5-F9BB-4744-9BFF-6A869C763909Q34013796-0A856AFD-7D2B-43D5-B448-F3EDB3826255Q34707452-8ED4CC89-7A99-4D26-B9BD-85D962DC5B2AQ35001132-00B1CC0B-5D04-4B74-B19C-1D45A91C6315Q35083258-E1C88A4A-15A5-4E9F-8D95-0124EAF6BA7BQ35144933-ED866FBC-AEFE-4C86-BDCA-52B418871859Q35567932-20F94A65-278A-4FEC-9537-8BE282A8FE9EQ35568527-2A713698-E694-44B6-B5C8-2A980EFE1E05Q35657367-28E77942-29D6-4046-9E42-27B992B0BF8FQ35661305-68FCFB34-032C-414B-B021-A54CBEA883D4Q35750889-28772F19-2C8D-4B5C-9DA1-7E42A1296E29Q36445968-A3897DAD-22EF-4D3D-968A-05AA233C5814Q36512538-4F865F96-E346-4C0D-B9D0-7E6874F6A25BQ36612553-9C514F0D-0E0C-4B75-A96B-4ACE9011BE5FQ36715246-E297DA59-8B1B-41E0-BC55-094226E0FFC4Q37134517-8C628D36-FEF3-4DCB-AF9B-2AF36B34BF26Q37146019-EF0B998D-573D-4442-A7E9-DFD62C636305Q37146038-C7019A32-B1B9-4064-972A-7E37515CE1A4Q37222206-FBEB2E52-BB41-480C-94D4-2C5B8723F9ACQ37263146-B8577B4D-C837-479F-94BA-EDBCD8904CEAQ37724605-2CDEE669-978F-424D-BA2B-82773D857078Q37980495-EE297D2D-3DD4-4673-B601-65B61DD05C72Q38235662-B5C7363C-3420-4C8A-8774-1ED1223D8539Q38283075-2854A97D-529F-4769-94B5-A21392A9DCC3Q38348119-5ECABDF0-D94A-42DA-BF67-DBC6F5E4C42CQ38834981-9BD1501E-8167-4F0D-86AC-79D6ED205C15Q39009800-27DFFCD0-7386-4CAF-8737-F575ABC95CC4Q39096716-20F36130-93E9-4CC8-BD07-982DD3653B90Q39757098-1ACEF0C8-F036-41D8-9550-6B2EAA8A9BDDQ39819964-3337F5F7-864B-4551-986A-CA2B36B67549Q41241661-7B972987-0165-4680-9A64-E2F26467B42FQ41791233-E5A1D179-DD12-4F34-9810-B13ACD84D821Q42285087-B6FE42B8-2FAD-4871-B4AF-696032E4FF75
P2860
Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Preferential suppression of tr ...... my 8 myelodysplastic syndrome.
@ast
Preferential suppression of tr ...... my 8 myelodysplastic syndrome.
@en
type
label
Preferential suppression of tr ...... my 8 myelodysplastic syndrome.
@ast
Preferential suppression of tr ...... my 8 myelodysplastic syndrome.
@en
prefLabel
Preferential suppression of tr ...... my 8 myelodysplastic syndrome.
@ast
Preferential suppression of tr ...... my 8 myelodysplastic syndrome.
@en
P2093
P2860
P1433
P1476
Preferential suppression of tr ...... my 8 myelodysplastic syndrome.
@en
P2093
A John Barrett
Antonio M Risitano
Elaine M Sloand
Keyvan Keyvanafar
Lori Mainwaring
Monika Fuhrer
Neal S Young
Shakti Ramkissoon
P2860
P304
P356
10.1182/BLOOD-2004-05-2017
P407
P50
P577
2005-04-12T00:00:00Z